« Atlas Shire's Up Investors Rare Disease Portfolio | Main | GE Enters Turnkey Bioplant Partnership for Emerging Nations »

12/16/2011

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a0120a77f675b970b01543864b796970c

Listed below are links to weblogs that reference Preaching to the Choir on Merck's R&D Spend:

Comments

Feed You can follow this conversation by subscribing to the comment feed for this post.

pharma reviews

Fitch Ratings has published an analysis of Big Pharma's drug development activity since the beginning of the year and 22 new late-stage programs were added to their pipelines, mostly from in-licensing and acquisition.
And i also agree with your arguments.
than x for invent this website for viewers and users.

pharma reviews

I agree whole-heartedly with Mike Wokasch's comments on industry views of Merck's CEO Ken Frazer staying the course with R&D spending. I do think it is consistent with Merck's mission to remain a leading supplier of innovative medicines that are clinically effective and differentiated -- and that can prove their value. See post from Pharma Reform blog. Let the view from the cheap seats from analysts who are interested in short-term financial results be damned. AMEN.

Pharma Reviews

One big caution though -- auto makers haven't historically always been able to recoup their costs of capital -- not exactly a ringing endorsement for someone who wants to compete in pharma industry with dwindling capital markets to support it. Auto makers may have the most to teach in manufacturing and reducing costs there.

The comments to this entry are closed.

My Photo
Blog powered by Typepad
Member since 12/2009
Bookmark and Share

August 2014

Sun Mon Tue Wed Thu Fri Sat
          1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31            

Innovate on Purpose

In the Pipeline

Life Sci VC


visited 6 states (46.1%)
Create your own visited map of Canada